國(guó)家獸藥產(chǎn)業(yè)技術(shù)創(chuàng)新聯(lián)盟 National veterinary drug industry technology innovation alliance |
用戶登錄
聯(lián)系我們
|
服務(wù)創(chuàng)造價(jià)值、存在造就未來
自2019年12月新型冠狀病毒肺炎(coronavirus disease 2019,COVID-19)暴發(fā)以來,世界各國(guó)相繼出現(xiàn)了大量新型冠狀病毒(severe acute respiratory syndrome coronavirus 2,SARS-CoV-2)感染病例。SARS-CoV-2對(duì)全球公共衛(wèi)生安全造成了巨大威脅。疫情發(fā)生以來,相關(guān)科研人員從SARS-CoV-2的病原學(xué)特點(diǎn)、流行病學(xué)特征、病原學(xué)檢測(cè)、治療與愈后癥狀等方面進(jìn)行了研究。本文對(duì)上述幾個(gè)方面的研究成果進(jìn)行了匯總。研究發(fā)現(xiàn):SARS-CoV-2以其遺傳多樣性和重組頻繁的特點(diǎn)不斷產(chǎn)生變異體,以更大的傳播力感染人群;目前已知的2種傳染途徑為跨物種傳播和人際傳播,其中飛沫傳播和接觸傳播是人際傳播的主要傳播途徑;感染人群遍布各個(gè)年齡段,其中患有慢性疾病的老年人更容易發(fā)展成危重病人;臨床檢測(cè)時(shí)聯(lián)合核酸和抗原抗體檢測(cè),將有助于提高SARS-CoV-2感染的檢出率并排除其他冠狀病毒感染的可能性;目前尚未有治療COVID-19的特效藥物,臨床上廣泛使用廣譜抗病毒藥物或中藥來治療各種癥狀;全球各國(guó)正在加緊研發(fā)SARS-CoV-2疫苗,部分疫苗已進(jìn)入臨床試驗(yàn)階段。本文有助于全面了解SARS-CoV-2的研究狀況,也為其后續(xù)研究及防治提供了參考。
Research Progress on SARS-CoV-2
A large number of cases infected with severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)have appeared in many countries since December 2019 when the outbreak of coronavirus disease 2019(COVID-19)occurred,which has posed huge threat to global public health. SARS-CoV-2 has been studied by relevant researchers based on its etiology,epidemiological characteristics,etiology detection,therapy and prognosis since the outbreak,and the research results were summarized in this paper as follows:variants had been produced by SARS-CoV-2 due to its genetic diversity and frequent recombination,which had infected an increasing number of people with stronger transmission;two pathways including cross-species and interpersonal transmission had been known at present,in which,the main pathways of interpersonal transmission included droplet and contact transmission;people at all ages might be infected,especially the elderly with chronic diseases were more likely to become critical patients;the detection rate might be improved by the combination of detection of nucleic acid and antigen antibody that could eliminate the possibility of other coronavirus infection;no effective drugs for COVID-19 had been available at present,instead,broad-spectrum antiviral drugs or traditional Chinese medicine were widely used in clinical practice;the development of vaccines against SARS-CoV-2 had been sped up by all countries,and some vaccines had been at clinical trial stage. The status of development of SARS-CoV-2 were summarized in this paper,which also provided some references for future study and control of it.
全文下載鏈接:https://kns.cnki.net/KCMS/detail/detail.aspx?dbcode=CJFQ&dbname=CJFDAUTO&filename=ZGDW202007015&v=MjY0MzRxVHJXTTFGckNVUjdxZllPZG9GeTNoVkwzUFB5clBlYkc0SE5ITXFJOUVZWVI4ZVgxTHV4WVM3RGgxVDM=
國(guó)家獸藥產(chǎn)業(yè)技術(shù)創(chuàng)新聯(lián)盟 National veterinary drug industry technology innovation alliance |
掃一掃 |
聯(lián)系電話:010-62103991轉(zhuǎn)611 聯(lián)系地址:北京市海淀區(qū)中關(guān)村南大街8號(hào) 備案:京ICP備20024024號(hào) |